physIQ’s eVO2Max™ demonstrates breakout ability to estimate cardiopulmonary functional capacity from wearable sensor data during daily routine activity

December 14, 2022 |

4 min read

physIQ today announced a novel approach to estimating maximum oxygen utilization (VO2Max) using wearable biosensors and deep neural network technology.

Innovative approach can deliver high-fidelity cardiopulmonary exercise test results comparable to gold-standard testing with a wearable sensor during routine daily activities
Eliminates need for in-clinic testing and exhaustive physical activity while providing an accurate real-world view into patient health.
physIQ’s estimated VO₂Max (eVO2Max^™) was recently presented as an invited oral abstract at the 2022 American Heart Association Scientific Sessions

CHICAGO--(BUSINESS WIRE)-- physIQ today announced a novel approach to estimating maximum oxygen utilization (VO₂Max) using wearable biosensors and deep neural network technology. This innovative biomarker, eVO2Max, can be generated using 24 hours of continuous vital signs and activity data captured during routine daily activities. This enables remote assessment at higher frequency and convenience than by in-clinic tests of cardiopulmonary functional capacity, such as the gold standard, cardiopulmonary exercise test (CPET), and the less accurate surrogate six-minute walk test (6MWT).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005398/en/

The accurate determination of cardiopulmonary functional capacity can provide crucial insight during pharmaceutical trials into the effectiveness of therapies targeting preservation or enhancement of cardiopulmonary function and quality of life for patients. In medical practice, it also has the potential to innovate remote monitoring and care of patients with chronic cardiopulmonary disease, by providing visibility into patient status and identifying early signs of decompensation. physIQ developed eVO2Max to meet the need for accurate and objective functional testing in a rising geriatric population amidst increasingly prevalent cardiopulmonary diseases.

Unlike CPET and 6MWT, which typically require in-clinic visits and extensive patient activity in a sophisticated clinical environment, physIQ’s eVO2Max is performed in the patient’s routine, real-world home environment and requires no special activity protocol. The patient simply wears a small biosensor for several days and physIQ uses the wirelessly transmitted data to derive a daily VO₂Max estimate for clinician remote monitoring.

A variety of algorithmic estimators of VO₂Max have been released in the consumer fitness marketplace, but these target health-conscious consumers rather than medical patient populations, and typically require performing an interval of intense exercise. Moreover, such estimators have not demonstrated sufficient accuracy for clinical use.

Importantly, physIQ’s eVO2Max has shown a very high correlation (r= 0.91) to CPET-measured VO₂Max across a wide range of health statuses and age strata, including patients with compromised health. It uses proprietary deep neural network architecture with millions of hours of data from the company’s proprietary data trove to recognize the key features that capture cardiopulmonary performance during routine daily activities. The development and validation of eVO2Max was recently presented by physIQ Senior Data Scientist, Dylan Richards, in an invited oral abstract during the 2022 American Heart Association’s Scientific Sessions.

“Digital biomarkers from wearable sensors show great promise for serving up huge amounts of rich data to better understand how patients are doing in their real world lives,” said physIQ Chief Digital Health Officer Matt Pipke. “eVO2Max is an example of how rich data can update our health measurement toolset from data-sparse practices like the six-minute walk test to continuous, intelligent and easy-to-use evaluations with higher accuracy.”

About physIQ

physIQ delivers personalized medical insights that vastly improve patient outcomes. By combining proprietary AI and wearable biosensors, physIQ can continuously monitor patients in real-world environments and enable clinical trial sponsors and clinicians to proactively detect physiological decompositions, Improve the safety and efficacy of new therapies, and speed time to market. The company has published one of the most rigorous clinical studies to date in digital medicine and are pioneers in developing, validating, and achieving regulatory approval of Artificial Intelligence-based analytics. For more information, please visit www.physIQ.com. Follow us on Twitter and LinkedIn.